Primary B cell lymphomas of the skull base are uncommon and lack well-defined treatment guidelines. We report a case of diffuse, large B-cell lymphoma of the cavernous sinus with sphenoid sinus and clival extension, treated with partial resection, chemotherapy, and proton beam irradiation. To our knowledge, this is the first report of a skull-base lymphoma treated with protons. A 53-year-old female presented with a two-month history of diplopia, persistent headaches, and paresthesia over the left side of her mouth. A skull MRI revealed an enhancing mass in the right cavernous sinus and right sphenoid sinus. Transsphenoidal subtotal resection of the mass confirmed the presence of a diffuse, large B-cell lymphoma. Treatment consisted of CHOP-R chemotherapy and locoregional radiation with protons.
Objective and Importance
Non-Hodgkin's lymphomas (NHL) as a group represent the fifth most common cancer in the Western world, and are increasing in incidence and mortality (1). They consist of uncontrolled monoclonal proliferations of B or T lymphocytes in lymphoid tissues and organs throughout the body. Sites commonly involved include the spleen, bone marrow, and peripheral lymph nodes (1). Approximately 10% of reported NHL cases will arise in extranodal sites, such as the head and neck, gastrointestinal tract, or bone (2). Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of NHL. DLBCL frequently presents as an enlarging mass or masses with symptoms reflecting the anatomic location. DLBCL and other high-grade non-Hodgkin's lymphomas can rapidly become fatal if left untreated (1). In this report, we describe a primary highgrade, diffuse, large B-cell lymphoma arising in the cavernous sinus and extending into the clivus and sphenoid sinus. This is a rare primary site for an extranodal lymphoma; only a few case reports exist in the literature (2) (3) (4) . We discuss the multimodality management of these tumors and address the rationale for utilizing proton irradiation in this case. Protons are charged subatomic particles, unique in radiotherapy in that their depth of penetration can be controlled; this allows for exquisite dose conformality, resulting in lower volumes of normal brain receiving low to moderate doses of radiation. To our knowledge, this is the first report of a skull-base lymphoma treated with conformal protons.
Clinical Presentation
A 53-year-old female reported to our Emergency Department in January of 2004 with a two-month history of diplopia, persistent headaches, and paresthesia over the left side of her mouth. She reported that two weeks prior, a brain mass had been seen on MRI at another facility and that she was subsequently referred to our medical center for multidisciplinary oncologic management. She did not complain of any other symptoms, and denied fevers, weight loss, or night sweats. Initial examination revealed a right lateral rectus palsy and extremity ataxia. The remainder of her history and physical examination were unremarkable. An MRI of the skull base obtained at the time of presentation revealed an enhancing 3.0 × 2.6 × 2.4 cm mass located in the right cavernous sinus and extending to the right sphenoid sinus. No other abnormalities were present. The mass was initially thought to be a meningioma by virtue of its appearance and location on MRI. Our neurosurgeons concurred and recommended a transsphenoidal resection. However, upon admission, the patient was diagnosed with a tooth abscess requiring surgical treatment outside of our facility. Resection was, therefore, delayed until complete recovery was achieved.
In February, a follow-up MRI of the skull base demonstrated the same mass but now with extension along the superior aspect of the clivus and suprasellar region, not seen on the previous scan. There was now complete encasement of the right internal carotid artery within the cavernous sinus, without evidence of compression or stenosis. No distortion of the optic chiasm was seen, and no other abnormalities or masses were noted. The patient's symptoms had remained stable during this interval.
Intervention or Technique
Resection of the mass was attempted through a transsphenoidal approach in March 2004. The patient tolerated the procedure well, with some residual post-operative perioral numbness. She did not experience any further complications. Post-operative MRI revealed that approximately 50% of the mass was resected, with the intracavernous portion remaining. Pathology revealed a diffuse, large B-cell lymphoma with invasion of adjacent bony and cartilaginous structures. Flow cytometric studies revealed the expression of Ki-67, CD20, CD79, and CD45.
In April, the patient was referred to medical oncology for a staging work-up, including a bone marrow biopsy and CT scans of the chest, abdomen and pelvis, all of which were negative. She received chemotherapy from May to mid-June, consisting of four cycles of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) with adjuvant rituximab. The patient tolerated the chemotherapy well but developed some expected side effects including alopecia, and nausea and vomiting the first several days after each cycle. Following chemotherapy, her headaches resolved and her diplopia improved, being present only with extreme left lateral gaze.
She was seen in late June for possible adjuvant radiation therapy. We recommended adjuvant locoregional radiation therapy, and ordered a CT scan for radiotherapy planning and a follow-up diagnostic MRI of the brain. On these scans we appreciated residual disease in the right sphenoid sinus and clivus. Compared to the pre-chemotherapy, post-surgical volume, the mass had regressed by 20% to 30% and was moderately less enhancing.
Radiation treatment began three weeks after the last cycle of chemotherapy, in mid-July, and was directed at the post-chemotherapy residual mass using a shrinking-field technique. Although we used low to moderate doses of radiation, we employed conformal protons to minimize the volume of normal brain tissue receiving these doses. The initial field (CTV1) included the residual enhancing mass and the entire clivus, with an additional 0.5 cm margin to target possible adjacent subclinical disease. This was treated with right and left lateral and superior oblique beams inclined at 45 degrees; these beams were alternated daily with one beam employed per day to a total dose of 36 Cobalt-Gray Equivalent (CGE). The boost field (CTV2) included the residual enhancing mass alone, plus a 0.5 cm margin for the same reason mentioned above. Right and left lateral beams were used and alternated in the same fashion for an additional 9 CGE; the total dose delivered was 45 CGE. Orthogonal radiographs were taken daily to triangulate and adjust patient position on the order of 0.5 mm and 0.5 degrees of collimator rotation; such an approach permits a 3 mm PTV margin to account for set-up uncertainty for patients treated in a mask. An additional 5 to 7 mm of margin was added for penumbra, depending on the beam energy utilized.
The patient completed treatment. Early in her treatment course, she developed progressive dyspepsia, nausea and, vomiting refractory to prochlorperazine, requiring steroid treatment. Towards the end of her course, she developed mild numbness and tingling of the left face, fingertips, and toes, decreased hearing in the left ear, and difficulty with left hand movements. Following an evaluation, our neurologists attributed these symptoms to vincristine toxicity; in their opinion, radiation may have helped these neurological deficits become clinically apparent. Three weeks after completing radiation, her hearing and left-hand movements had returned to normal, with persistence of the numbness and tingling mentioned above. We employed proton radiation to minimize the dose received by other structures in the head. To indicate the extent to which this reduction was achieved, we performed dose distribution analyses of the proton plan we employed, in comparison with a three-dimensional conformal x-ray plan. Figure 1 , consisting of an isodose color-wash depicting the cumulative deposition of dose, and Figure 2 , a series of dose-volume histograms, indicate the dose reduction.
Conclusions
Primary lymphomas of the skull base are uncommon and often present with headaches and cranial nerve deficits. They frequently invade the cavernous sinus and impinge upon the oculomotor, trochlear, abducens, and trigeminal nerves that course through it. Further growth can cause encasement and later obstruction of the intracavernous portion of the internal carotid arteries. The above can lead to a clinical picture known as the cavernous sinus syndrome, which usually includes intractable headaches or retro-orbital pain, diplopia, lateral gaze palsy, and facial paresthesia (5). Headaches and diplopia seem to be the most common symptoms, and such a presentation should prompt a differential diagnosis for sellar masses, including chordomas, chondrosarcomas, meningiomas, lymphomas, and metastatic carcinomas (2).
Non-Hodgkin's lymphomas in general are frequently treated with and respond to a combination of chemotherapy and radiotherapy. A review of several reports suggests that the best treatment outcomes are obtained with the CHOP regimen, given at three-week intervals (6). Rituximab is a therapeutic antibody directed against the CD20 surface antigen frequently present of lymphoma cells; its use in conjunction with CHOP augments treatment response in lymphomas that express the CD20 antigen (7). Chemotherapy is frequently followed by locoregional radiotherapy to a dose of 30 to 40 gray (Gy) (6). For primary bone lymphomas, including those of the skull base, management is similar to other nodal and extranodal primary sites of a similar stage and grade; for localized presentations, a minimal dose of 35 Gy is recommended to the entire bone or area at risk, which is then frequently followed by a boost (8).
No specific treatment guidelines exist for skullbase lymphomas, and reports of primary clival lymphomas Figure 2 : Dose-volume histograms demonstrating difference in dose received by the right optic nerve (upper left), the left optic nerve (upper right), the right cochlea (lower left), and the GTV (lower right); 3-D conformal x-ray doses are represented by the green line, conformal protons by the red. In every case, the use of conformal protons allows for a substantial sparing of normal tissues as compared to 3-D x-rays, while the radiation dose to the GTV remains essentially identical. The three-dimensional (3-D) conformal x-ray plan is on the left; the conformal proton plan is on the right. The dose is displayed as a color-wash, varying from 100% (red) to 30% (dark blue). The gross tumor volume (GTV) is represented by the solid red contour. Note that in both views the volume of tissue receiving a moderate radiation dose is substantially greater when 3-D x rays are employed as opposed to protons. treated with radiation are sparse. Nakatomi et al. (4) reported a case wherein gamma knife radiosurgery was used as the primary and sole treatment modality. Dose was prescribed to the 40% isodose line with a maximal dose of 37.5 Gy within the target volume. The local area remained controlled, but an adjacent left petroclival recurrence developed seven months post-treatment and was surgically salvaged 13 months after treatment. The patient died 31 months post-treatment from an aspiration pneumonia; an autopsy done at the time revealed no active tumor cells in the bone marrow or CNS. Other authors have used various chemoradiation regimens. Metellus et al. (1) reported on a patient who remained disease-free three years after completing six months of M-COPPA and 50 Gy of locoregional irradiation. Tanaka et al. (9) reported a very similar case and outcome utilizing CHOP chemotherapy.
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In case presented here, the mass was initially thought to be a meningioma according to its appearance and location on MRI, and a surgical resection was attempted via a transsphenoidal approach. The therapeutic role of surgical resection in NHL is not clear, but a biopsy is standard to make a pathologic diagnosis (1). In this case, a subtotal resection of approximately 50% was achieved. This was followed by a standard chemotherapeutic regimen and proton beam irradiation for adjuvant locoregional radiotherapy.
Protons are charged particles; they are used in radiotherapy because they have a finite range of depth penetration in tissue and deposit the majority of their energy at the end of their range; this is termed the "Bragg peak" effect. By modulating proton beams and effectively spreading out the Bragg peak to encompass the target, one obtains conformation in all three dimensions with relatively few beams and a low integral dose (low to moderate dose of radiation delivered to surrounding normal tissues). Though protons are best known for their ability to deliver high doses to radioresistant tumors, such as chordomas and chondrosarcomas of the craniospinal axis, they are also valuable in treating radiosensitive tumors that are surrounded by critical normal structures such as the brain, because integral dose is minimized. This is in fact why we employed protons in this case: to minimize the volume of normal brain structures receiving a low to moderate dose of radiation.
In summary, primary diffuse large B-cell lymphomas of the skull base are uncommon. They can be managed similarly to other nodal and extranodal non-Hodgkin's lymphomas of a similar risk profile. Adjuvant locoregional radiotherapy calls for moderate doses that do not exceed the tolerance of adjacent normal structures. Thus, rapid dose fall-off between target volumes and adjacent normal structures becomes less important, and minimization of integral dose gains relative importance. Though sophisticated x-ray treatment delivery systems can achieve the former, protons are uniquely suited to accomplish the latter; they can be of great value in treating tumors to doses below the tolerance of adjacent normal structures.
